Lawrence Steinman
Publication Details
-
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.
Neurology. 2012; (6): 531-7
There is a significant unmet need for serum biomarkers in relapsing-remitting multiple sclerosis (RRMS) that are predictive of therapeutic response to disease-modifying therapies. Following a recent Stanford study which reported that pretreatment levels of serum interleukin (IL)-17F could predict poor response to interferon-β (IFNβ) therapy, we sought to validate the finding using samples from a large clinical trial.
Help